stockportfolio.pro
Stocks / ALMS vs SUPN
ALMS vs SUPN
Alumis Inc. and Supernus Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Alumis Inc. (ALMS) | Supernus Pharmaceuticals, Inc. (SUPN) | |
|---|---|---|
| Market cap | $2.6B | $2.6B |
| Revenue (latest FY) | $24.05M | $718.95M |
| Net income (latest FY) | $-243.32M | $-38.55M |
| Revenue growth (5y CAGR) | — | 6.7% |
| Net margin | -1011.7% | -5.4% |
| Return on equity | -80.8% | -3.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 9 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ALMS — free Open SUPN — freeFrequently asked questions
Which is bigger, ALMS or SUPN?
Alumis Inc. is larger by market capitalization — $2.6B versus $2.6B.
Which grows faster, ALMS or SUPN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.